Implications of lipid biology for the pathogenesis of schizophrenia

References

• Yehuda S, Mostofsky D. Handbook of essential fatty acid biology. Biochemistry, physiology, and behavioral neurobiology. Human Press, Totwa, NJ 1997
   Google Scholar
• Farstad M. Determination of fatty acids in cerebrospinal fluid. v. The fatty acid content in the total lipids of cerebrospinal fluid in psychiatric patients. Scandinavian Journal of Clinical and Laboratory Investigations 1966; 18: 343–346
   PubMed Web of Science ®Google Scholar
• Rotrosen J, Wolkin A. Phopholipid and prostaglandin hypotheses of schizophrenia. Psychopharmacology the third generation of progress, H Meltzer. Raven, New York 1987; 759–764
   Google Scholar
• Keshavan M S, Mallinger A G, Pettegrew J W, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Research 1993; 49: 89–95
   PubMed Web of Science ®Google Scholar
• Ripova D, Strunecka A, Nemcova V, Farska I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiological Research 1997; 46: 59–68
   PubMed Web of Science ®Google Scholar
• Heleniak E, O'Desky I. Histamine and prostaglandins in schizophrenia: revisited. Medical Hypotheses 1999; 52: 37–42
   PubMed Web of Science ®Google Scholar
• Horrobin D, Glen A, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994; 13: 195–207
   PubMed Web of Science ®Google Scholar
• co1st International workshop on cell membrane pathology in schizophreniaAugusta, Georgia30–31, March, 1993, Proceedings Schizophrenia Research 1994; 13: 191–270
   Google Scholar
• Proceedings of 2nd International Workshop on Cell Membrane Pathology in Schizophrenia LondonUnited Kingdom6–8, October, 1995 Special issue dedicated to the memory of Dr. Sukdeb Mukherjee. Prostaglandins, Leukotriens, and Essential Fatty Acids 1996; 55:. 1–122
   Google Scholar
• Peet M, Glen I, Horrobin D. Phospholipid spectrum disorder. Psychiatry. 1. Marius, Carnforth, UK 1999
   Google Scholar
• MacQueen G M, Rosebush P I, Mazurek M F. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. Journal of Neuropsychiatry and Clinical Neurosciences 1998; 10: 10–19
   PubMed Web of Science ®Google Scholar
• Yao J K, Reddy R D, van Kammen D P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287–310
   PubMed Web of Science ®Google Scholar
• Vaddadi K, Gilleard C, Soosai E, Polonowita A, Gibson R, Burrows G. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophrenia Research 1996; 20: 287–294
   PubMed Web of Science ®Google Scholar
• Garcia-Segura L M, Azcoitia I, DonCarlos L L. Neuroprotection by estradiol. Progress in Neurobiololgy 2001; 63: 29–60
   PubMed Web of Science ®Google Scholar
• Agranoff B W, Joyce A B, Hajra A K. Lipids. Basic neurochemistry: molecular, cellular and medical aspects6th edn., G J Siegel, B W Agranoff. Lippincott-Raven, Philadelphia 1998; 47–68
   Google Scholar
• Torres I C, Mira L, Ornelas C P, Melim A. Study of the effects of dietary fish intake on serum lipids and lipoproteins in two populations with different dietary habits. British Journal of Nutrition 2000; 83: 371–379
   PubMed Web of Science ®Google Scholar
• Cunnane S C, Francescutti V, Brenna J T, Crawford M A. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000; 35: 105–111
   PubMed Web of Science ®Google Scholar
• Farooqui A A, Horrocks L A, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chemistry and Physics of Lipids 2000; 106: 1–29
   PubMed Web of Science ®Google Scholar
• Bazan N G, Packard M G, Teather L, Allan G. Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochemistry Internation 1997; 30: 225–231
   PubMed Web of Science ®Google Scholar
• Akbarian S, Kim J J, Potkin S G, Hetrick W P, Bunney W E, Jr, Jones E G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Archives of General Psychiatry 1996; 53: 425–436
   PubMed Web of Science ®Google Scholar
• McGlashan T H, Hoffman R E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Archives of General Psychiatry 2000; 57: 637–648
   PubMed Web of Science ®Google Scholar
• Devane W A, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proceedings of the National Academy of Sciences of the USA. 1994; 91: 6698–6701
   Google Scholar
• Glass M. The role of cannabinoids in neurodegenerative diseases. Progress in Neurology, Psychology and Biological Psychiatry 2001; 25: 743–765
   PubMed Web of Science ®Google Scholar
• Brown A S, Susser E S, Butler P D, Richardson Andrews R, Kaufmann C A, Gorman J M. Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Journal of Nervous and Mental Disease 1996; 184: 71–85
   PubMed Web of Science ®Google Scholar
• Innis S M, Sprecher H, Hachey D, Edmond J, Anderson R E. Neonatal polyunsaturated fatty acid metabolism. Lipids 1999; 34: 139–149
   PubMed Web of Science ®Google Scholar
• Peet M, Poole J, Laugharne J. Breastfeeding, Neurodevelopment, and Schizophrenia. Phospholipid Spectrum Disorder in Psychiatry, M Peet, I Glen, D Horrobin. Marius, Carnforth, UK 1999; 159–166
   Google Scholar
• McCreadie R G. The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: preliminary results and hypotheses. British Journal of Psychiatry 1997; 170: 334–337
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okazaki Y, Akaho R, et al. Type of feeding during infancy and later development of schizophrenia. Schizophrenia Research 2000; 42: 79–82
   PubMed Web of Science ®Google Scholar
• Leask S J, Done D J, Crow T J, Richards M, Jones P B. No association between breast-feeding and adult psychosis in two national birth cohorts. British Journal of Psychiatry 2000; 177: 218–221
   PubMed Web of Science ®Google Scholar
• Mrazek P J, Haggerty R J. New directions in definition. Reducing risks for mental disorders frontiers for preventive intervention research1st edn., P J Mrazek, R J Haggerty. National Academy Press, Washington, DC 1994; 19–29
   Google Scholar
• Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29: 697–701
   PubMed Web of Science ®Google Scholar
• Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica 1988; 78: 587–591
   PubMed Web of Science ®Google Scholar
• Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Australian and New Zealand Journal of Psychiatry 2000; 34(Suppl.)S26–S34, discussion S35–38
   PubMed Web of Science ®Google Scholar
• Mahadik S P, Mulchandoni M, Mahabaleshwar H V, Ranjekar P K. Cultural and socioeconomic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia. Phospholipid spectrum disorder in psychiatry1st edn., M Peet, I Glen, D Horrobin. Marius, Carnforth, UK 1999; 167–179
   Google Scholar
• Stoll A L. Fish consumption, depression, and suicidality in a general population. Archives of General Psychiatry 2001; 58: 512–513
   PubMed Web of Science ®Google Scholar
• Tanskanen A, Hibbeln J R, Tuomilehto J, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatric Services 2001; 52: 529–531
   PubMed Web of Science ®Google Scholar
• Mellsop G W. Schizophrenia and rheumatoid arthritis. Australian and New Zealand Journal of Psychiatry 1972; 6: 214
   PubMed Web of Science ®Google Scholar
• Horrobin D. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1: 936–937
   PubMed Web of Science ®Google Scholar
• Oken R J, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophrenia Bulletin 1999; 25: 625–638
   PubMed Web of Science ®Google Scholar
• Morrow J D, Awad J A, Oates J A, Roberts L J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. Journal of Investigational Dermatology 1992; 98: 812–815
   PubMed Web of Science ®Google Scholar
• Hoffer A. Adverse effects of niacin in emergent psychosis. Journal of the American Medical Association 1969; 207: 1355
   PubMed Web of Science ®Google Scholar
• Horrobin D F. Niacin flushing, prostaglandin E3 and evening primrose oil. A possible objective test monitoring therapy in schizophrenia. Journal of Orthomolecular Psychiatry 1980; 9: 33–34
   Google Scholar
• Fiedler P, Wolkin A, Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biological Psychiatry 1986; 21: 1347–1350
   PubMed Web of Science ®Google Scholar
• Wilson D W, Douglass A B. Niacin skin flush is not diagnostic of schizophrenia. Biological Psychiatry 1986; 21: 974–977
   PubMed Web of Science ®Google Scholar
• Rybakowski J, Weterle R. Niacin test in schizophrenia and affective illness. Biological Psychiatry 1991; 29: 834–836
   PubMed Web of Science ®Google Scholar
• Hudson C J, Lin A, Cogan S, Cashman F, Warsh J J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biological Psychiatry 1997; 41: 507–513
   PubMed Web of Science ®Google Scholar
• Glen A I, Cooper S J, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin D F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996; 55: 9–15
   PubMed Web of Science ®Google Scholar
• Ward P E, Sutherland J, Glen E M, Glen A I. Niacin skin flush in schizophrenia: a preliminary report. Schizophrenia Research 1998; 29: 269–274
   PubMed Web of Science ®Google Scholar
• Shah S H, Vankar G K, Peet M, Ramchand C N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophrenia Research 2000; 43: 163–164
   PubMed Web of Science ®Google Scholar
• Glen A I, Glen E M, Horrobin D F, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophrenia Research 1994; 12: 53–61
   PubMed Web of Science ®Google Scholar
• Yao J K, van Kammen D P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophrenia Research 1994; 11: 209–216
   PubMed Web of Science ®Google Scholar
• Yao J K, van Kammen D P, Welker J A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994; 13: 217–226
   PubMed Web of Science ®Google Scholar
• Horrobin D F, Bennett C N. The membrane phospholipid concept of schizophrenia. Search for the causes of schizophrenia. Balance of the century, W F Gattaz, H Haefner. Springer, Darmstadt 1999; IV: 261–279
   Google Scholar
• Fenton W S, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 2000; 47: 8–21
   PubMed Web of Science ®Google Scholar
• Yao J K, van Kammen D P, Gurklis J A. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Research 1996; 60: 11–21
   PubMed Web of Science ®Google Scholar
• Connor W E, Neuringer M, Lin D S. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. Journal of Lipid Research 1990; 31: 237–247
   PubMed Web of Science ®Google Scholar
• Horrobin D F, Manku M S, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 1991; 30: 795–805
   PubMed Web of Science ®Google Scholar
• Yao J K, Leonard S, Reddy R D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Research 2000; 42: 7–17
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne J D, Mellor J, Ramchand C N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids 1996; 55: 71–75
   PubMed Web of Science ®Google Scholar
• Six D A, Dennis E A. The expanding superfamily of phospholipase A (2) enzymes: classification and characterization. Biochimica Biophysica Acta 2000; 1488: 1–19
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Brunner J. Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996; 55: 109–113
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research 1995; 16: 1–6
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Hubner C V, Nevalainen T J, Thuren T, Kinnunen P K. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biological Psychiatry 1990; 28: 495–501
   PubMed Web of Science ®Google Scholar
• Ross B M, Hudson C, Erlich J, Warsh J J, Kish S J. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Archives of General Psychiatry 1997; 54: 487–494
   PubMed Web of Science ®Google Scholar
• Noponen M, Sanfilipo M, Samanich K, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry 1993; 34: 641–649
   PubMed Web of Science ®Google Scholar
• Albers M, Meurer H, Marki F, Klotz J. Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry 1993; 26: 94–98
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Nevalainen T J, Kinnunen P K. [Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia]. Fortschritte der Neurologie und Psychiatrie 1990; 58: 148–153, (In German.)
   PubMed Web of Science ®Google Scholar
• Gattaz W F, Kollisch M, Thuren T, Virtanen J A, Kinnunen P K. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biological Psychiatry 1987; 22: 421–426
   PubMed Web of Science ®Google Scholar
• Hudson C, Gotowiec A, Seeman M, Warsh J, Ross B. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biological Psychiatry 1999; 46: 401–405
   PubMed Web of Science ®Google Scholar
• Ross B M, Turenne S, Moszczynska A, Warsh J J, Kish S J. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Research 1999; 821: 407–413
   PubMed Web of Science ®Google Scholar
• Ross M B. Brain and blood phospholipase activity in psychiatric disorders. Phospholipid spectrum disorder in psychiatry1st edn., M Peet, I Glen, D Horrobin. Marius, Carnforth, UK 1999; 23–31
   Google Scholar
• Hudson C J, Kennedy J L, Gotowiec A, et al. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophrenia Research 1996; 21: 111–116
   PubMed Web of Science ®Google Scholar
• Wei J, Lee K H, Hemmings G P. Is the cPLA2 gene associated with schizophrenia?. Molecular Psychiatry 1998; 3: 480–481
   PubMed Web of Science ®Google Scholar
• Peet M, Ramchand C N, Lee J, et al. Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia. Psychiatric Genetics 1998; 8: 191–192
   PubMed Web of Science ®Google Scholar
• Doris A, Wahle K, MacDonald A, et al. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophrenia Research 1998; 31: 185–196
   PubMed Web of Science ®Google Scholar
• Frieboes R M, Moises H W, Gattaz W F, et al. Lack of association between schizophrenia and the phospholipase-A (2) genes cPLA2 and sPLA2. American Journal of Medical Genetics 2001; 105: 246–249
   PubMed Web of Science ®Google Scholar
• Waldo M C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophrenia Research 1999; 40: 49–53
   PubMed Web of Science ®Google Scholar
• Stevens J D. The distribution of the phospholipid fractions in the red cell membrane of schizophrenics. Schizophrenia Bulletin 1972; 6: 60–61
   Google Scholar
• Henn F A. The biological concepts of schizophrenia. Perspectives in schizophrenia research, C Baxter, T Melnachuk. Raven, New York 1980; 209
   Google Scholar
• Lautin A, Cordasco D M, Segarnick D J, et al. Red cell phospholipids in schizophrenia. Life Sciences 1982; 31: 3051–3056
   PubMed Web of Science ®Google Scholar
• Hitzemann R, Hirschowitz J, Garver D. Membrane abnormalities in the psychoses and affective disorders. Journal of Psychiatric Research 1984; 18: 319–326
   PubMed Web of Science ®Google Scholar
• Thomas E A, Dean B, Pavey G, Sutcliffe J G. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proceedings of the National Academy of Sciences of the USA. 2001; 98: 4066–4071
   Google Scholar
• Phillips M, Erickson G A, Sabas M, Smith J P, Greenberg J. Volatile organic compounds in the breath of patients with schizophrenia. Journal of Clinical Pathology 1995; 48: 466–469
   PubMed Web of Science ®Google Scholar
• Potwarka J J, Drost D J, Williamson P C. Quantifying 1H decoupled in vivo 31P brain spectra. NMR in Biomedicine 1999; 12: 8–14
   PubMed Web of Science ®Google Scholar
• Vance A L, Velakoulis D, Maruff P, Wood S J, Desmond P, Pantelis C. Magnetic resonance spectroscopy and schizophrenia: what have we learnt?. Australian and New Zealand Journal of Psychiatry 2000; 34: 14–25
   PubMed Web of Science ®Google Scholar
• Kegeles L S, Humaran T J, Mann J J. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biological Psychiatry 1998; 44: 382–398
   PubMed Web of Science ®Google Scholar
• Keshavan M S, Stanley J A, Pettegrew J W. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings-part II. Biological Psychiatry 2000; 48: 369–380
   PubMed Web of Science ®Google Scholar
• Pettegrew J W, Keshavan M S, Panchalingam K, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Archives of General Psychiatry 1991; 48: 563–568
   PubMed Web of Science ®Google Scholar
• Keshavan M S, Pettegrew J W. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. Archives of General Psychiatry 1991; 48: 1112
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. American Journal of Psychiatry 1999; 156: 1205–1208
   PubMed Web of Science ®Google Scholar
• Yao J K, Stanley J A, Reddy R D, Keshavan M S, Pettegrew J W. Correlation between RBC fatty acids and 31P MRS brain measures in schizophrenia. Society for Biological Psychiatry 2000; 47: 41
   Web of Science ®Google Scholar
• Stanley J A, Williamson P C, Drost D J, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy [published erratum appears in Archives of General Psychiatry 1995 October; 52 (10): 799]. Archives of General Psychiatry 1995; 52: 399–406
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Fukuzako T, Kodama S, Hashiguchi T, Takigawa M, Fujimoto T. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 1999; 21: 542–549
   PubMed Web of Science ®Google Scholar
• Potwarka J J, Drost D J, Williamson P C, et al. A 1H-decoupled 31 P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biological Psychiatry 1999; 45: 687–693
   PubMed Web of Science ®Google Scholar
• Bluml S, Tan J, Harris K, et al. Quantitative proton-decoupled 31 P MRS of the schizophrenic brain in vivo. Journal of Computer Assisted Tomography 1999; 23: 272–275
   PubMed Web of Science ®Google Scholar
• Velakoulis D, Wood S J, McGorry P D, Pantelis C. Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Australian and New Zealand Journal of Psychiatry 2000; 34: 113–126
   PubMed Web of Science ®Google Scholar
• Wood S J, Velakoulis D, Pantelis C. Volume of parahippocampal gyrus and hippocampus in schizophrenia. British Journal of Psychiatry 1999; 175: 388–389
   PubMed Web of Science ®Google Scholar
• Marteinsdottir I, Horrobin D, Stenfors C, Theodorsson E, Mathe A. Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain. Progresses in Neuropsychopharmacolology and Biological Psychiatry 1998; 22: 1007–1021
   PubMed Web of Science ®Google Scholar
• Stanley J A, Pettegrew J W. Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of vivo (31) P brain spectra. Magnnetic Resonance Medicine 2001; 45: 390–396
   PubMed Web of Science ®Google Scholar
• Stanley J A, Williamson P C, Drost D J, et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophrenia Research 1994; 13: 209–215
   PubMed Web of Science ®Google Scholar
• Williamson P C, Drost D J, Stanley J A, Carr T J, Morrison S, Mersky H. Localized phosporus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Archives of General Psychiatry 1991; 48: 578
   PubMed Web of Science ®Google Scholar
• Hinsberger A D, Williamson P C, Carr T J, et al. Magnetic resonance imaging volume tric and phosphorus 31 magnetic resonance spectroscopy measurements in schizophrenia. Journal of Psychiatry and Neuroscience 1997; 22: 111–117
   PubMed Web of Science ®Google Scholar
• Calabrese G, Deicken R F, Fein G, Merrin E L, Schoenfeld F, Weiner M W. 31 Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biological Psychiatry 1992; 32: 26–32
   PubMed Web of Science ®Google Scholar
• Deicken R F, Calabrese G, Merrin E L, Vinogradov S, Fein G, Weiner M W. Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: a 31 phosphorous magnetic resonance spectroscopic imaging study. Biological Psychiatry 1995; 38: 279–286
   PubMed Web of Science ®Google Scholar
• Deicken R F, Calabrese G, Merrin E L, et al. 31 phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biological Psychiatry 1994; 36: 503–510
   PubMed Web of Science ®Google Scholar
• Deicken R F, Merrin E L, Floyd T C, Weiner M W. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophrenia Research 1995; 14: 177–181
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Takeuchi K, Ueyama K, et al. 31 P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms. European Archives of Psychiatry and Clinical Neuroscience 1994; 244: 236–240
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Fukuzako T, Takeuchi K, et al. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Progress in Neuro- Psychopharmacology and Biological Psychiatry 1996; 20: 629–640
   PubMed Web of Science ®Google Scholar
• Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Research 1994; 55: 223–235
   PubMed Web of Science ®Google Scholar
• Shioiri T, Someya T, Murashita J, et al. Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Research 1997; 76: 113–122
   PubMed Web of Science ®Google Scholar
• Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Research 1995; 61: 151–160
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Nakano T, Takano T, Hokazono Y, Asakura T, Tsuji T. Study of chronic schizophrenics using 31 P magnetic resonance chemical shift imaging. Acta Psychiatrica Scandinavica 1992; 86: 455–462
   PubMed Web of Science ®Google Scholar
• O'Callaghan E, Redmond O, Ennis R, et al. Initial investigation of the left temporoparietal region in schizophrenia by 31 P magnetic resonance spectroscopy. Biological Psychiatry 1991; 29: 1149–1152
   PubMed Web of Science ®Google Scholar
• Volz H P, Hubner G, Rzanny R, et al. High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31 phosphorus magnetic resonance spectroscopic and neuropsychological investigation. Schizophrenia Research 1998; 31: 37–47
   PubMed Web of Science ®Google Scholar
• Volz H P, Rzanny R, Rossger G, et al. 31 Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics – a study including 50 patients and 36 controls. Biological Psychiatry 1998; 44: 399–404
   PubMed Web of Science ®Google Scholar
• Wainwright P E, Jalali E, Mutsaers L M, Bell R, Cvitkovic S. An imbalance of dietary essential fatty acids retards behavioral development in mice. Physiology and Behaviour 1999; 66: 833–839
   PubMed Web of Science ®Google Scholar
• Wainwright P. Essential Fatty Acids and behaviour. Is there a role for the Eicosanoids?. Handbook of essential fatty acid biology biochemistry, physiology, and behavioral neurobiology, S Yehuda, D Mostofky. Human Press, Totwa, NJ 1997; 299–341
   Google Scholar
• Goustard-Langelier B, Guesnet P, Durand G, Antoine J M, Alessandri J M. n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Lipids 1999; 34: 5–16
   PubMed Web of Science ®Google Scholar
• Lin D S, Connor W E, Anderson G J, Neuringer M. Effects of dietary n-3 fatty acids on the phospholipid molecular species of monkey brain. Journal of Neurochemistry 1990; 55: 1200–1207
   PubMed Web of Science ®Google Scholar
• Saku N, Kobayashi J, Kitamura S. Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages activated by silica. Prostaglandins, Leukotriens, and Essential Fatty Acids 1999; 61: 51–54
   PubMed Web of Science ®Google Scholar
• Whelan J. Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. Journal of Nutrition 1996; 126: 1086S–1091S
   PubMed Web of Science ®Google Scholar
• Padma M, Das U N. Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation in macrophage tumor (AK-5) cells in vitro. Prostaglandins, Leukotriens and Essential Fatty Acids 1999; 60: 55–63
   PubMed Web of Science ®Google Scholar
• Seung Kim H F, Weeber E J, Sweatt J D, Stoll A L, Marangell L B. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Molecular Psychiatry 2001; 6: 246–248
   PubMed Web of Science ®Google Scholar
• Manji H K, Lenox R H. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biological Psychiatry 1999; 46: 1328–1351
   PubMed Web of Science ®Google Scholar
• Vaddadi K, Gilleard C, Mindham R, Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology 1986; 88: 362–367
   PubMed Web of Science ®Google Scholar
• Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. American Journal of Psychiatry 1986; 143: 912–914
   PubMed Web of Science ®Google Scholar
• Vaddadi K, Courtney P, Gilleard C, Manku M, Horrobin D. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989; 27: 313–323
   PubMed Web of Science ®Google Scholar
• Rudin D. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biological Psychiatry 1981; 16: 837–850
   PubMed Web of Science ®Google Scholar
• Mellor J E, Laugharne J DE, Peet M. Omega-3 Fatty acid supplementation in Schizophrenic Patients. Human Psychopharmacology 1996; 11: 39–46
   Web of Science ®Google Scholar
• Shah S, Vankar G K, Telang S D, Ramchchand C N, Peet M. Eicosapentanoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophrenia Research 1998; 29: 158
   Web of Science ®Google Scholar
• Peet M, Brind J, Ramchand C N, Shah S, Vankar G K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 2001; 49: 243–251
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin D F. A multicenter trial of Ethyl Eicosapentaenoic acid in schizophrenia. Schizophrenia Research 2000; 41: 225
   Web of Science ®Google Scholar
• Fenton W S, Dickerson F B, Boronow J J, et al. Placebocontrolled trial of omega-3 fatty acid in schizophrenia. VIII International Congress on Schizophrenia Research 2001; 49: 225, 227
   PubMed Web of Science ®Google Scholar
• Nichols P D, Virtue P, Mooney B P, Elliot N G, Yearsley G K. Seafood the good food. The oil (fat) content and composition of Australian commercial fishes, shellfishes and crustaceans. CSIRO and the Fisheries Research and Development Corperation, Hobart 1998
   Google Scholar
• Thomas E A, Danielson P E, Nelson P A, et al. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism of neuroeptic pharmacotherapy. Journal of Neurochemistry 2001; 76: 789–796
   PubMed Web of Science ®Google Scholar
• Stoll A L, Severus W E, Freeman M P, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry 1999; 56: 407–412
   PubMed Web of Science ®Google Scholar